Article
COA Commends 340B Drug Discount Accountability Act
The Community Oncology Alliance (COA) has voiced its support of the 340B Drug Discount Accountability Act, which would require hospitals to report their total 340B drug purchases and pay a small 0.1% user fee to the Health Resources and Services Administration.
The Community Oncology Alliance (COA) has voiced its support of the 340B Drug Discount Accountability Act (HR 6240), introduced by Representative Chris Collins, R-New York, which would require hospitals to report their total 340B drug purchases and pay a small 0.1% user fee to the Health Resources and Services Administration (HRSA).
The legislation will ensure that HRSA receives additional resources needed to properly oversee and administer the program, according to COA. The user fees would go toward program oversight, audits, and monitoring of the program.
Grantees and non-hospital covered entities would be exempt. The bill would also give HRSA “direct-hire authority” for new employees to implement and conduct the oversight.
Read more about the legislation and the full press release here.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
